Drugs / MK2578
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00968617 | Nov 2009 → Apr 2010 | anemia, chronic kidney disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00924781 | Jun 2009 → Apr 2010 | anemia, chronic kidney disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK2578 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968617 ↗ |
| Route | Intravenous | “MK2578 was to be administered intravenously (IV).” NCT00924781 ↗ |